Emerging SARS-CoV-2 Variants of Concern (VOCs): An Impending Global Crisis DOI Creative Commons

Angel Yun-Kuan Thye,

Jodi Woan‐Fei Law, Priyia Pusparajah

et al.

Biomedicines, Journal Year: 2021, Volume and Issue: 9(10), P. 1303 - 1303

Published: Sept. 23, 2021

The worldwide battle against the SARS-CoV-2 virus rages on, with millions infected and many innocent lives lost. causative organism, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is a beta that belongs to Coronaviridae family. Many clinically significant variants have emerged, as virus’s genome prone various mutations, leading antigenic drift resulting in evasion of host immune recognition. current concern (VOCs) include B.1.1.7 (Alpha), B.1.351 (Beta), B.1.617/B.1.617.2 (Delta), P.1 (Gamma). emerging contain important mutations on spike protein, deleterious consequences, such invasion vaccine escape. These adverse effects result increased transmissibility, morbidity, mortality detection by existing or currently available diagnostic tests, potentially delaying diagnosis treatment. This review discusses key present VOC strains provides insights into how these allow for greater transmissibility than progenitor strain. Continuous monitoring surveillance play vital role preventing controlling spread.

Language: Английский

Detection of a SARS-CoV-2 variant of concern in South Africa DOI Creative Commons
Houriiyah Tegally, Eduan Wilkinson, Marta Giovanetti

et al.

Nature, Journal Year: 2021, Volume and Issue: 592(7854), P. 438 - 443

Published: March 9, 2021

Language: Английский

Citations

1691
Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa DOI Creative Commons
Raquel Viana, Sikhulile Moyo, Daniel G. Amoako

et al.

Nature, Journal Year: 2022, Volume and Issue: 603(7902), P. 679 - 686

Published: Jan. 7, 2022

Abstract The SARS-CoV-2 epidemic in southern Africa has been characterized by three distinct waves. first was associated with a mix of lineages, while the second and third waves were driven Beta (B.1.351) Delta (B.1.617.2) variants, respectively 1–3 . In November 2021, genomic surveillance teams South Botswana detected new variant rapid resurgence infections Gauteng province, Africa. Within days genome being uploaded, it designated concern (Omicron, B.1.1.529) World Health Organization and, within weeks, had identified 87 countries. Omicron is exceptional for carrying over 30 mutations spike glycoprotein, which are predicted to influence antibody neutralization function 4 Here we describe profile early transmission dynamics Omicron, highlighting spread regions high levels population immunity.

Language: Английский

Citations

1614
Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity DOI Creative Commons
Wilfredo F. García-Beltrán, Evan C. Lam, Kerri St. Denis

et al.

Cell, Journal Year: 2021, Volume and Issue: 184(9), P. 2372 - 2383.e9

Published: March 12, 2021

Language: Английский

Citations

1435
SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma DOI Creative Commons
Constantinos Kurt Wibmer, Frances Ayres, Tandile Hermanus

et al.

Nature Medicine, Journal Year: 2021, Volume and Issue: 27(4), P. 622 - 625

Published: March 2, 2021

Language: Английский

Citations

1235
Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera DOI Creative Commons
Daming Zhou, Wanwisa Dejnirattisai, Piyada Supasa

et al.

Cell, Journal Year: 2021, Volume and Issue: 184(9), P. 2348 - 2361.e6

Published: Feb. 23, 2021

Highlights•Reduced B.1.351 neutralization by mAbs and sera induced early SARS-CoV-2 isolates•B.1.351 titer reduced 8- to 9-fold for Pfizer AstraZeneca vaccinees•E484K, K417N, N501Y cause widespread escape from mAbs•NTD deletion in abrogates a potent neutralizing human mAbSummaryThe race produce vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) began when the first sequence was published, this forms basis currently deployed globally. Independent lineages of have recently been reported: UK, B.1.1.7; South Africa, B.1.351; Brazil, P.1. These variants multiple changes immunodominant spike protein that facilitates viral cell entry via angiotensin-converting enzyme-2 (ACE2) receptor. Mutations receptor recognition site on are great concern their potential immune escape. Here, we describe structure-function analysis using large cohort convalescent vaccinee serum samples. The receptor-binding domain mutations provide tighter ACE2 binding monoclonal antibody largely driven E484K, although K417N act together some important classes. In number cases, it would appear vaccine offers limited protection variant.Graphical abstract

Language: Английский

Citations

1100
The biological and clinical significance of emerging SARS-CoV-2 variants DOI Creative Commons
Kaiming Tao, Philip L. Tzou, Janin Nouhin

et al.

Nature Reviews Genetics, Journal Year: 2021, Volume and Issue: 22(12), P. 757 - 773

Published: Sept. 17, 2021

Language: Английский

Citations

985
Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum DOI Creative Commons
Chang Liu, Helen M. Ginn, Wanwisa Dejnirattisai

et al.

Cell, Journal Year: 2021, Volume and Issue: 184(16), P. 4220 - 4236.e13

Published: June 17, 2021

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has undergone progressive change, with variants conferring advantage rapidly becoming dominant lineages, e.g., B.1.617. With apparent increased transmissibility, variant B.1.617.2 contributed to the current wave of infection ravaging Indian subcontinent and been designated a concern in United Kingdom. Here we study ability monoclonal antibodies convalescent vaccine sera neutralize B.1.617.1 B.1.617.2, complement this structural analyses Fab/receptor binding domain (RBD) complexes, map antigenic space variants. Neutralization both viruses is reduced compared ancestral Wuhan-related strains, but there no evidence widespread antibody escape as seen B.1.351. However, B.1.351 P.1 showed markedly more reduction neutralization suggesting that individuals infected previously by these may be susceptible reinfection B.1.617.2. This observation provides important new insights for immunization policy future vaccines non-immune populations.

Language: Английский

Citations

713
Impact of SARS-CoV-2 variants on the total CD4+ and CD8+ T cell reactivity in infected or vaccinated individuals DOI Creative Commons
Alison Tarke, John Sidney,

Nils Methot

et al.

Cell Reports Medicine, Journal Year: 2021, Volume and Issue: 2(7), P. 100355 - 100355

Published: July 1, 2021

The emergence of SARS-CoV-2 variants with evidence antibody escape highlight the importance addressing whether total CD4

Language: Английский

Citations

624
LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants DOI Creative Commons
Kathryn Westendorf,

Stefanie Žentelis,

Lingshu Wang

et al.

Cell Reports, Journal Year: 2022, Volume and Issue: 39(7), P. 110812 - 110812

Published: April 25, 2022

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-neutralizing monoclonal antibodies (mAbs) can reduce the risk of hospitalization from disease 2019 (COVID-19) when administered early. However, SARS-CoV-2 variants concern (VOCs) have negatively affected therapeutic use some authorized mAbs. Using a high-throughput B cell screening pipeline, we isolated LY-CoV1404 (bebtelovimab), highly potent spike glycoprotein receptor binding domain (RBD)-specific antibody. potently neutralizes authentic SARS-CoV-2, B.1.1.7, B.1.351, and B.1.617.2. In pseudovirus neutralization studies, variants, including B.1.617.2, B.1.427/B.1.429, P.1, B.1.526, B.1.1.529, BA.2 subvariant. Structural analysis reveals that contact residues epitope are conserved, except for N439 N501. The neutralizing activity is unaffected by most common mutations at these positions (N439K N501Y). broad relatively conserved suggest has potential to be an effective agent treat all known variants.

Language: Английский

Citations

402
Tackling COVID-19 with neutralizing monoclonal antibodies DOI Creative Commons
Davide Corti, Lisa A. Purcell,

Gyorgy Snell

et al.

Cell, Journal Year: 2021, Volume and Issue: 184(12), P. 3086 - 3108

Published: May 26, 2021

Language: Английский

Citations

373